

This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



## Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

### INHIBITION OF HIV-1 REPLICATION BY THE CRE-LOXP HAMMERHEAD RIBOZYME

Yuichiro Habu<sup>a</sup>; Naoko Miyano-Kurosaki<sup>b</sup>; Hiroaki Takeuchi<sup>a</sup>; Norihiko Matsumoto<sup>a</sup>; Yutaka Tamura<sup>b</sup>; Hiroshi Takaku<sup>a</sup>

<sup>a</sup> Department of Industrial Chemistry, Chiba Institute of Technology, Chiba, Japan <sup>b</sup> High Technology Research Center, Chiba Institute of Technology, Chiba, Japan

Online publication date: 31 March 2001

**To cite this Article** Habu, Yuichiro , Miyano-Kurosaki, Naoko , Takeuchi, Hiroaki , Matsumoto, Norihiko , Tamura, Yutaka and Takaku, Hiroshi(2001) 'INHIBITION OF HIV-1 REPLICATION BY THE CRE-LOXP HAMMERHEAD RIBOZYME', *Nucleosides, Nucleotides and Nucleic Acids*, 20: 4, 723 — 726

**To link to this Article:** DOI: 10.1081/NCN-100002359

**URL:** <http://dx.doi.org/10.1081/NCN-100002359>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

## INHIBITION OF HIV-1 REPLICATION BY THE CRE-LOXP HAMMERHEAD RIBOZYME

Yuichiro Habu,<sup>1</sup> Naoko Miyano-Kurosaki,<sup>2</sup> Hiroaki Takeuchi,<sup>1</sup>  
Norihiko Matsumoto,<sup>1</sup> Yutaka Tamura,<sup>2</sup> and Hiroshi Takaku<sup>1,2,\*</sup>

<sup>1</sup>Department of Industrial Chemistry and

<sup>2</sup>High Technology Research Center, Chiba Institute of Technology,  
2-17-1 Tsudanuma, Narashino, Chiba 275-0016, Japan

### ABSTRACT

Antiviral strategies to suppress productive human immunodeficiency virus type 1 (HIV-1) replication have included the generation of gene products that provide intracellular inhibition of an essential viral protein or RNA. The potential of such a molecular genetic intervention was examined by using the Cre/loxP recombination system. In this study, we constructed a loxP-cassette vector (LTR-ribozyme) and a Cre recombinase expression vector (LTR-Cre). The transcription of the ribozyme and Cre genes was designed to be driven from the LTR promoter. These vectors were transiently transfected into COS cells along with the viral expression vector, and inhibited the expression of viral protein in COS cells. These data further support the potential of this system as a therapeutic agent for HIV-1.

### INTRODUCTION

An alternative strategy for the management of human immunodeficiency virus type 1 (HIV-1) infection has been the use of antiviral genes that are delivered to uninfected cells as either RNA or DNA and provide intercellular protection from the virus. Several strategies targeting HIV-1 gene expression have been shown to be effective in inhibiting virus replication, and these include intracellular expression

---

\*Corresponding author. Fax: +81-474-71-8764; E-mail: takaku@ic.it-chiba.ac.jp


of transdominant proteins, antisense molecules, ribozymes, and intracellular antibodies. The potential of such a molecular genetic intervention was examined by using the Cre-loxP recombination system (1,2). We describe here the function of an HIV-1 dependent ribozyme expression vector, with which the site-specific excision of loxP sequences can be achieved by using the Cre-loxP system as a molecular switch in an acute infection.

## RESULTS AND DISCUSSION

In our previous study, the cDNA inserted between the loxP sequence required promoter activation to synthesize the Cre protein by recombination, so we examined its expression (3). The gene encoding luciferase was co-transfected with the Cre expression vector (pBS185) (4–6) into COS cells, and after two days, the luciferase activity was measured. We confirmed that it functioned as a plasmid DNA from the cDNA inserted between the loxP sequence in the Cre protein, and that its quantity depended on promoter activation. In addition to the loxP cassette vector, we also analyzed lox-Rz, a recombinant ribozyme vector targeted against the LTR U5 portion of the HIV-1<sub>NL4-3</sub> strain. We also constructed a plasmid in which the HIV-1 LTR promoter drives the expression of the Cre protein. Plasmids expressing lox-Rz, LTR-Cre, the luciferase gene, and other parts of the HIV-1 genome, except env and nef, were transfected into COS cells. After two days, the luciferase activities in these cells were measured (Fig. 1).


As a result, transiently expressed lox-Rz and LTR-Cre were found to inhibit the HIV-1 expression by the luciferase assay.

Furthermore, plasmids containing the Cre/loxP system and expressing the HIV-1 gene were transfected into COS cells. After two days, the amounts of HIV-1 gag p24 antigen in these cells were measured. The LTR-Cre/lox-Rz system strongly suppressed the production of gag p24 antigen (Fig. 2).



**Figure 1.** Inhibition of luciferase activity by the ribozyme expressed from the Cre/loxP system after Cre recombinase introduction (LTR-Cre). The lox-Rz expressed the strongest inhibition of the luciferase activity in COS cells.





**Figure 2.** Inhibition of HIV-1 gag p24 antigen production. The lox-Rz showed significant suppression of the HIV-1 gag p24 antigen expression in COS cells.

Our results suggest that the LTR-Cre/lox-Rz recombination system could be useful in the establishment of an effective genetic therapy against HIV-1 infection.

## EXPERIMENTAL

### Construction of Plasmids

The ribozyme expression vector and the loxP cassette vector, pBS246 (GIBCO BRL), were digested with KpnI, phenol/chloroform extracted, ethanol precipitated, and ligated to the KpnI sites (lox-Rz). The plasmid containing the Cre gene, pBS185 (GIBCO BRL), was digested with SstI and NarI. The termini of the resultant insert DNA were blunted with T4 DNA polymerase. This insert DNA was ligated with the LTR-luc vector DNA, which had been digested with HindIII and SalI and made blunt by treatment with T4 DNA polymerase.

### Intracellular Recombination of lox-Rz

COS cells were grown in Dulbecco's modified Eagle's medium (D-MEM) supplemented with 10%-heat-inactivated fetal bovine serum (FBS), 50 units/ml penicillin, and 50 units/ml streptomycin in a moist atmosphere with 5% CO<sub>2</sub> at 37°C. The cultures, in 24-well plates (1 × 10<sup>4</sup> cells/1 ml/well), were washed with PBS(-), and 500 μl of serum free D-MEM were added to each well. The ribozyme expression vector lox-Rz was cotransfected with a 10-fold (by weight) excess of the Cre expression plasmid LTR-Cre and a 0.1-fold portion (by weight) of the plasmid expressing the luciferase gene and other parts of the HIV-1 genome (except *env* and *nef*), pNL-luc (0.1 μg of lox-Rz and 1 μg of LTR-Cre and 0.01 μg of pNL-luc) using 3 μl of the FuGENE<sup>TM</sup> 6 transfection reagent (Roche Diagnostics K.K.). DNA-FuGENE<sup>TM</sup> 6 complexes were added to the cells, which were then incubated at 37°C. At 4 h posttransfection, 500 μl of D-MEM containing 20% FBS were



added to each cell culture. After 48 h, the cells were washed twice with PBS(-), 200  $\mu$ l of cell lysis solution (PicaGene<sup>®</sup>) were added, and the mixtures were incubated for 15 min. The lysates were harvested and centrifuged at 12,000 rpm for 3 min. In the luciferase assay, 10  $\mu$ l of cell lysate were used. To measure the relative light units (RLU), a luminometer (LUMAT LB 9507; EG&G BERTHOLD) was used.

Anti-HIV-activity of lox-Rz. COS cells were incubated in D-MEM at 37°C and in a 5% CO<sub>2</sub> atmosphere for 24 hours. The cultures, in 60mm dishes (3  $\times$  10<sup>5</sup> cells/3 ml), were washed with PBS(-), and 1  $\mu$ g of lox-Rz was cotransfected with 1  $\mu$ g of LTR-Cre using 3  $\mu$ l of the FuGENE<sup>™</sup> 6 transfection reagent. After 24 h, 0.5  $\mu$ g of pNL4-3 complexed with 1  $\mu$ l of the FuGENE<sup>™</sup> 6 transfection reagent was added, and the cells were cultured for 24 more h. Anti-HIV activity was determined by measuring the amount of p24 antigen in the supernatant, using an HIV-1 p24 ELISA.

## ACKNOWLEDGMENT

This work was supported by a Grant-in-Aid for High Technology Research and Scientific Research, No. 09309011, from the Ministry of Education, Science, Sports, and Culture, Japan.

## REFERENCES

1. Flowers, C. C.; Woffendin, C.; Petryniak, J.; Yang, S.; Nabel, G. J. *J. Virol.*, **1997**, *71*, 2685–2692.
2. Sauer, B. *Methods in Enzymology*, **1993**, *225*, 890–900.
3. Habu, Y.; Takeuchi, H.; Tamura, Y.; Miyano-Kurosaki, N.; Takai, K.; Takaku, H. *Nucleic Acids Symp. Ser.* **1999**, *42*, 295–296.
4. Abremski, K.; Hoess, R.; Stenberg, N. *Cell*, **1983**, *32*, 1301–1311.
5. Hoess, R.; Abremski, K. *J. Mol. Biol.*, **1985**, *181*, 351–362.
6. Stenberg, N.; Sauer, B.; Hoess, R.; Abremski, K. *J. Mol. Biol.*, **1986**, *187*, 197–212.



## **Request Permission or Order Reprints Instantly!**

Interested in copying and sharing this article? In most cases, U.S. Copyright Law requires that you get permission from the article's rightsholder before using copyrighted content.

All information and materials found in this article, including but not limited to text, trademarks, patents, logos, graphics and images (the "Materials"), are the copyrighted works and other forms of intellectual property of Marcel Dekker, Inc., or its licensors. All rights not expressly granted are reserved.

Get permission to lawfully reproduce and distribute the Materials or order reprints quickly and painlessly. Simply click on the "Request Permission/Reprints Here" link below and follow the instructions. Visit the [U.S. Copyright Office](#) for information on Fair Use limitations of U.S. copyright law. Please refer to The Association of American Publishers' (AAP) website for guidelines on [Fair Use in the Classroom](#).

The Materials are for your personal use only and cannot be reformatted, reposted, resold or distributed by electronic means or otherwise without permission from Marcel Dekker, Inc. Marcel Dekker, Inc. grants you the limited right to display the Materials only on your personal computer or personal wireless device, and to copy and download single copies of such Materials provided that any copyright, trademark or other notice appearing on such Materials is also retained by, displayed, copied or downloaded as part of the Materials and is not removed or obscured, and provided you do not edit, modify, alter or enhance the Materials. Please refer to our [Website User Agreement](#) for more details.

**[Order now!](#)**

Reprints of this article can also be ordered at

<http://www.dekker.com/servlet/product/DOI/101081NCN100002359>